 |
|
Parkinson Disease Survival
A Population-Based Study
Letterio Morgante, MD;
Giuseppe Salemi, MD;
Francesca Meneghini, ScD;
Antonio Enrico Di Rosa, MD;
Antonio Epifanio, MD;
Francesco Grigoletto, ScD;
Paolo Ragonese, MD;
Francesco Patti, MD;
Arturo Reggio, MD;
Raoul Di Perri, MD;
Giovanni Savettieri, MD
Arch Neurol. 2000;57:507-512.
Objective To evaluate whether the survival of patients with Parkinson disease (PD) is shorter than that of the general population.
Design Survival was investigated in a cohort of patients with PD previously identified during a population-based prevalence study (prevalence day, November 1, 1987; reference follow-up date, October 31, 1995). The survival of patients with PD was compared with that of a control sample randomly selected from the same population (2 controls for each case, matched for age, sex, and study municipality). The causes of death in the 2 groups were also compared. Both univariate and multivariate survival analyses were performed to investigate the association with disease-related variables.
Setting A door-to-door 2-phase prevalence survey performed in 3 Sicilian municipalities.
Patients Fifty-nine patients with PD and 118 controls.
Results Patients with PD showed a high risk of death (relative risk, 2.3; 95% confidence interval, 1.60-3.39). Greater age at November 1, 1987, high Hoehn-Yahr score, and lack of levodopa therapy were associated with a lower survival on univariate analysis. Multivariate analysis confirmed the association between shorter survival among patients with PD and greater age on November 1, 1987. One-way analysis of variance indicated a different effect of levodopa therapy according to age. Multivariate analysis did not confirm this finding. Pneumonia was the cause of death most frequently associated with PD.
Conclusion This study indicates that patients with PD have a shorter survival time than the general population.
From the Department of Neurology, University of Messina, Messina (Drs Morgante, Di Rosa, Epifanio, and Di Perri), Department of Neurology, University of Palermo, Palermo (Drs Salemi, Ragonese, and Savettieri), Institute of Hygiene, University of Padua, Padua (Drs Meneghini and Grigoletto), and Department of Neurology, University of Catania, Catania (Drs Patti and Reggio), Italy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(4):613-614.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Features in Early Parkinson Disease and Survival
Lo et al.
Arch Neurol 2009;66:1353-1358.
ABSTRACT
| FULL TEXT
Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study
Driver et al.
Neurology 2008;70:1423-1430.
ABSTRACT
| FULL TEXT
Estimated life expectancy of Parkinson's patients compared with the UK population
Ishihara et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:1304-1309.
ABSTRACT
| FULL TEXT
Prognosis of Parkinson Disease: Risk of Dementia and Mortality: The Rotterdam Study
de Lau et al.
Arch Neurol 2005;62:1265-1269.
ABSTRACT
| FULL TEXT
Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort
Marras et al.
Neurology 2005;64:87-93.
ABSTRACT
| FULL TEXT
Mortality and Parkinson disease: A community based study
Herlofson et al.
Neurology 2004;62:937-942.
ABSTRACT
| FULL TEXT
The association of incident dementia with mortality in PD
Levy et al.
Neurology 2002;59:1708-1713.
ABSTRACT
| FULL TEXT
Medical Services Utilization and Prognosis in Parkinson Disease: A Population-Based Study
Parashos et al.
Mayo Clin Proc. 2002;77:918-925.
ABSTRACT
Deep brain stimulation in the treatment of Parkinson's disease: A cost-effectiveness analysis
Tomaszewski and Holloway
Neurology 2001;57:663-671.
ABSTRACT
| FULL TEXT
|
